Company intelligence / Profile preview

Anocca

Södertälje, Stockholms län, Swedenanocca.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 1

Overview

Anocca received CTA approval in March 2025 for its first-in-human VIDAR-1 trial testing ANOC-001 in advanced pancreatic cancer. The trial will be conducted in Sweden, Denmark, Germany, and The Netherlands, with initiation planned for Q2 2025. This marks Anocca's transition to a clinical-stage company and is the first regulatory authorization in Europe to study a non-viral gene-edited TCR-T therapy.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: T-cell receptor-engineered T cell (TCR-T) therapies
Industry: Biotech

Drug pipeline

18 assets

ANOC-001

17 more assets in the full pipeline.

Request access →

Partnerships

Shinobi Therapeutics

Beyond the preview

Go deeper on Anocca.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anocca.

Explore the full profile